Parisi Gray Wealth Management Purchases 2,010 Shares of Eli Lilly and Company (NYSE:LLY)

Parisi Gray Wealth Management increased its position in Eli Lilly and Company (NYSE:LLY) by 58.9% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 5,423 shares of the company’s stock after acquiring an additional 2,010 shares during the period. Eli Lilly and Company comprises about 1.3% of Parisi Gray Wealth Management’s investment portfolio, making the stock its 19th biggest holding. Parisi Gray Wealth Management’s holdings in Eli Lilly and Company were worth $3,161,000 at the end of the most recent reporting period.

Several other large investors also recently modified their holdings of LLY. Thompson Investment Management Inc. bought a new stake in Eli Lilly and Company during the third quarter valued at about $27,000. Retirement Group LLC boosted its stake in shares of Eli Lilly and Company by 159.1% in the second quarter. Retirement Group LLC now owns 57 shares of the company’s stock worth $27,000 after acquiring an additional 35 shares during the period. Legacy Financial Group LLC bought a new position in shares of Eli Lilly and Company in the third quarter worth about $35,000. Optiver Holding B.V. bought a new position in shares of Eli Lilly and Company in the third quarter worth about $36,000. Finally, Cornerstone Planning Group LLC bought a new position in shares of Eli Lilly and Company in the second quarter worth about $33,000. Institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company Trading Up 1.6 %

LLY traded up $12.24 during trading on Thursday, hitting $790.42. The company’s stock had a trading volume of 480,242 shares, compared to its average volume of 3,188,776. The stock has a market cap of $751.03 billion, a PE ratio of 134.26, a PEG ratio of 1.70 and a beta of 0.34. The company has a debt-to-equity ratio of 1.69, a current ratio of 0.94 and a quick ratio of 0.73. The firm’s 50 day moving average price is $727.96 and its 200-day moving average price is $636.01. Eli Lilly and Company has a twelve month low of $334.58 and a twelve month high of $800.78.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings results on Tuesday, February 6th. The company reported $2.49 EPS for the quarter, topping the consensus estimate of $2.30 by $0.19. The firm had revenue of $9.35 billion for the quarter, compared to analyst estimates of $8.95 billion. Eli Lilly and Company had a return on equity of 51.22% and a net margin of 15.36%. Eli Lilly and Company’s revenue for the quarter was up 28.1% on a year-over-year basis. During the same period in the previous year, the company posted $2.09 EPS. On average, analysts expect that Eli Lilly and Company will post 12.42 earnings per share for the current year.

Insider Activity

In other Eli Lilly and Company news, major shareholder Lilly Endowment Inc sold 34,538 shares of the business’s stock in a transaction on Tuesday, January 9th. The stock was sold at an average price of $631.81, for a total transaction of $21,821,453.78. Following the completion of the transaction, the insider now owns 99,719,884 shares in the company, valued at approximately $63,004,019,910.04. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. In the last ninety days, insiders sold 195,055 shares of company stock worth $125,254,657. 0.13% of the stock is currently owned by insiders.

Analyst Ratings Changes

Several research firms have weighed in on LLY. Morgan Stanley raised their price target on Eli Lilly and Company from $805.00 to $950.00 and gave the company an “overweight” rating in a report on Friday, February 16th. Bank of America raised their price objective on Eli Lilly and Company from $800.00 to $1,000.00 and gave the company a “buy” rating in a research note on Friday, March 1st. DZ Bank lowered Eli Lilly and Company from a “buy” rating to a “hold” rating and set a $820.00 price objective for the company. in a research note on Wednesday, February 21st. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $815.00 price objective on shares of Eli Lilly and Company in a research note on Tuesday, February 20th. Finally, Wells Fargo & Company raised their price objective on Eli Lilly and Company from $700.00 to $825.00 and gave the company an “overweight” rating in a research note on Tuesday, February 6th. Three equities research analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company. According to MarketBeat, Eli Lilly and Company currently has an average rating of “Moderate Buy” and a consensus price target of $689.52.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.